芦可替尼乳膏治疗中重度慢性手部湿疹的疗效与安全性
这项2期多中心随机双盲研究纳入186例中重度慢性手部湿疹成人患者,比较1.5%芦可替尼乳膏每日两次与赋形剂乳膏治疗16周的效果。结果显示芦可替尼组53.2%达到IGA-CHE 0/1且改善≥2级,显著高于赋形剂组的10.9%(P<.0001),瘙痒在第7天显著改善,安全性良好。
要点
- 1.5%芦可替尼乳膏每日两次治疗16周,IGA-CHE应答率53.2% vs 10.9%(P<.0001)。
- 安全性良好,无新安全信号,应用部位反应发生率3.2%。
核心结论
- 1.5%芦可替尼乳膏每日两次治疗16周可有效改善中重度非特应性慢性手部湿疹,且耐受性良好。
研究设计与样本
- 2期多中心随机双盲赋形剂对照研究,纳入北美和欧洲186例中重度慢性手部湿疹成人患者,按1:1随机分配至1.5%芦可替尼乳膏或赋形剂乳膏每日两次治疗16周。
主要发现
- 第16周达到IGA-CHE 0/1且较基线改善≥2级的患者比例为53.2%(芦可替尼组)vs 10.9%(赋形剂组),P<.0001。
- 研究期间观察到皮肤疼痛和生活质量改善,芦可替尼乳膏耐受性良好,无新安全信号,应用部位反应发生率3.2%。
临床怎么用
- 对于标准治疗未控制的中重度非特应性慢性手部湿疹亚型,1.5%芦可替尼乳膏每日两次可作为有效治疗选择。
局限性
- 样本量相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hand eczema (CHE) is a well-recognized inflammatory disorder. OBJECTIVE: To evaluate the efficacy and safety of 1.5% ruxolitinib cream in adults with moderate to severe CHE. METHODS: This phase 2 study enrolled adults with CHE from North America and Europe, an Investigator's Global Assessment-CHE score of 3/4, ≥1 prior CHE therapy, and no current or recent history (≤5 y) of atopic dermatitis. Patients were randomized 1:1 to twice-daily 1.5% ruxolitinib cream or vehicle cream for 16 weeks. RESULTS: Among 186 randomized patients, most who applied ruxolitinib cream achieved a score of 0 (clear) or 1 (almost clear) on the Investigator's Global Assessment-CHE scale with a 2-grade improvement from baseline at Week 16 (53.2% vs 10.9% [vehicle]; P < .0001; primary endpoint). Itch improvements (≥4-point improvement in numerical rating scale) were reported on Day 2 (9.1% vs 2.4%) and reached statistical significance on Day 7 (27.4% vs 9.0%; P = .0024). Improvements in skin pain and quality of life were reported during the study. Ruxolitinib cream was well tolerated, with no new safety signals and few (3.2%) application site reactions. LIMITATIONS: Relatively small sample size. CONCLUSION: Ruxolitinib cream represents an effective treatment option for nonatopic CHE subtypes that are not controlled with standard therapies.
引用
- Zirwas M, Fowler JF, Tsianakas A, et al. Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study. J Am Acad Dermatol. 2025. PMID: 40889714. doi:10.1016/j.jaad.2025.08.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。